Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 614

1.

Patient-Reported Barriers to Completing a Diagnostic Colonoscopy Following Abnormal Fecal Immunochemical Test Among Uninsured Patients.

Jetelina KK, Yudkin JS, Miller S, Berry E, Lieberman A, Gupta S, Balasubramanian BA.

J Gen Intern Med. 2019 Jun 21. doi: 10.1007/s11606-019-05117-0. [Epub ahead of print]

PMID:
31228053
2.

JNK2 in myeloid cells impairs insulin's vasodilator effects in muscle during early obesity development through perivascular adipose tissue dysfunction.

Meijer RI, Hoevenaars FP, Serné E, Yudkin JS, Kokhuis TJ, Weijers EM, van Hinsbergh VWM, Smulders YM, Eringa EC.

Am J Physiol Heart Circ Physiol. 2019 May 31. doi: 10.1152/ajpheart.00663.2018. [Epub ahead of print]

PMID:
31149833
3.

Analogue insulin as an essential medicine: the need for more evidence and lower prices.

Beran D, Hemmingsen B, Yudkin JS.

Lancet Diabetes Endocrinol. 2019 May;7(5):338. doi: 10.1016/S2213-8587(19)30111-1. Epub 2019 Mar 22. No abstract available.

PMID:
30910501
4.

Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection.

Hopkin G, Au A, Collier VJ, Yudkin JS, Basu S, Naci H.

Med Decis Making. 2019 Apr;39(3):264-277. doi: 10.1177/0272989X19835239. Epub 2019 Mar 15.

PMID:
30873906
5.

Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA-Brasil): an occupational cohort study in Brazil.

Schmidt MI, Bracco PA, Yudkin JS, Bensenor IM, Griep RH, Barreto SM, Castilhos CD, Duncan BB.

Lancet Diabetes Endocrinol. 2019 Apr;7(4):267-277. doi: 10.1016/S2213-8587(19)30058-0. Epub 2019 Feb 22.

PMID:
30803929
6.

Global public health starts at home: upstream approaches to global health training.

Oni T, Yudkin JS, Fonn S, Adongo P, Kaseje M, Ajuwon A, Doyal L, London L.

Lancet Glob Health. 2019 Mar;7(3):e301-e302. doi: 10.1016/S2214-109X(18)30558-8. No abstract available.

7.

Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.

Choi SE, Berkowitz SA, Yudkin JS, Naci H, Basu S.

Med Decis Making. 2019 Apr;39(3):239-252. doi: 10.1177/0272989X19829735. Epub 2019 Feb 15.

PMID:
30767632
8.

Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis.

Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Wild SH, Lipska KJ, Sussman JB, Beran D.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):25-33. doi: 10.1016/S2213-8587(18)30303-6. Epub 2018 Nov 21. Erratum in: Lancet Diabetes Endocrinol. 2019 Jan;7(1):e1.

PMID:
30470520
9.

Reducing chronic disease through changes in food aid: A microsimulation of nutrition and cardiometabolic disease among Palestinian refugees in the Middle East.

Basu S, Yudkin JS, Berkowitz SA, Jawad M, Millett C.

PLoS Med. 2018 Nov 20;15(11):e1002700. doi: 10.1371/journal.pmed.1002700. eCollection 2018 Nov.

10.

Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.

Beran D, Ewen M, Lipska K, Hirsch IB, Yudkin JS.

Curr Diab Rep. 2018 Jun 16;18(8):48. doi: 10.1007/s11892-018-1019-z. Review.

PMID:
29907884
11.

Erratum. Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective. Diabetes Care 2018;41:1125-1131.

Beran D, Hirsch IB, Yudkin JS.

Diabetes Care. 2018 Sep;41(9):2048. doi: 10.2337/dc18-er09a. Epub 2018 Jun 15. No abstract available.

12.

Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective.

Beran D, Hirsch IB, Yudkin JS.

Diabetes Care. 2018 Jun;41(6):1125-1131. doi: 10.2337/dc17-2123. Erratum in: Diabetes Care. 2018 Jun 15;:.

PMID:
29784696
13.

Associations of stunting in early childhood with cardiometabolic risk factors in adulthood.

De Lucia Rolfe E, de França GVA, Vianna CA, Gigante DP, Miranda JJ, Yudkin JS, Horta BL, Ong KK.

PLoS One. 2018 Apr 11;13(4):e0192196. doi: 10.1371/journal.pone.0192196. eCollection 2018.

14.

Inequalities in non-communicable diseases in Israel.

Yudkin JS.

Lancet. 2018 Feb 10;391(10120):536-537. doi: 10.1016/S0140-6736(17)32473-X. No abstract available.

PMID:
29617238
15.

Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.

Basu S, Sussman JB, Berkowitz SA, Hayward RA, Bertoni AG, Correa A, Mwasongwe S, Yudkin JS.

Diabetes Care. 2018 Mar;41(3):586-595. doi: 10.2337/dc17-2002. Epub 2017 Dec 21.

16.

Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.

Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS.

Lancet Diabetes Endocrinol. 2017 Oct;5(10):788-798. doi: 10.1016/S2213-8587(17)30221-8. Epub 2017 Aug 10.

17.

Diabetes in sub-Saharan Africa: from clinical care to health policy.

Atun R, Davies JI, Gale EAM, Bärnighausen T, Beran D, Kengne AP, Levitt NS, Mangugu FW, Nyirenda MJ, Ogle GD, Ramaiya K, Sewankambo NK, Sobngwi E, Tesfaye S, Yudkin JS, Basu S, Bommer C, Heesemann E, Manne-Goehler J, Postolovska I, Sagalova V, Vollmer S, Abbas ZG, Ammon B, Angamo MT, Annamreddi A, Awasthi A, Besançon S, Bhadriraju S, Binagwaho A, Burgess PI, Burton MJ, Chai J, Chilunga FP, Chipendo P, Conn A, Joel DR, Eagan AW, Gishoma C, Ho J, Jong S, Kakarmath SS, Khan Y, Kharel R, Kyle MA, Lee SC, Lichtman A, Malm CP, Mbaye MN, Muhimpundu MA, Mwagomba BM, Mwangi KJ, Nair M, Niyonsenga SP, Njuguna B, Okafor OLO, Okunade O, Park PH, Pastakia SD, Pekny C, Reja A, Rotimi CN, Rwunganira S, Sando D, Sarriera G, Sharma A, Sidibe A, Siraj ES, Syed AS, Van Acker K, Werfalli M.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):622-667. doi: 10.1016/S2213-8587(17)30181-X. Epub 2017 Jul 5. Review. No abstract available.

PMID:
28688818
18.

Genomic ancestry and education level independently influence abdominal fat distributions in a Brazilian admixed population.

França GVA, De Lucia Rolfe E, Horta BL, Gigante DP, Yudkin JS, Ong KK, Victora CG.

PLoS One. 2017 Jun 5;12(6):e0179085. doi: 10.1371/journal.pone.0179085. eCollection 2017. Erratum in: PLoS One. 2018 Apr 17;13(4):e0196265.

19.

Essential medicines and access to insulin.

Gill G, Yudkin JS, Tesfaye S, de Courten M, Gale E, Motala A, Ramaiya K, Unwin N, Wild S.

Lancet Diabetes Endocrinol. 2017 May;5(5):324-325. doi: 10.1016/S2213-8587(17)30090-6. Epub 2017 Mar 18. No abstract available.

PMID:
28330591
20.

Exercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function.

Boa BCS, Yudkin JS, van Hinsbergh VWM, Bouskela E, Eringa EC.

Br J Pharmacol. 2017 Oct;174(20):3466-3481. doi: 10.1111/bph.13732. Epub 2017 Mar 16. Review.

21.

The association of hyperglycaemia with prevalent tuberculosis: a population-based cross-sectional study.

Bailey SL, Ayles H, Beyers N, Godfrey-Faussett P, Muyoyeta M, du Toit E, Yudkin JS, Floyd S.

BMC Infect Dis. 2016 Dec 5;16(1):733.

22.

Diabetes diagnosis and care in sub-Saharan Africa: pooled analysis of individual data from 12 countries.

Manne-Goehler J, Atun R, Stokes A, Goehler A, Houinato D, Houehanou C, Hambou MM, Mbenza BL, Sobngwi E, Balde N, Mwangi JK, Gathecha G, Ngugi PW, Wesseh CS, Damasceno A, Lunet N, Bovet P, Labadarios D, Zuma K, Mayige M, Kagaruki G, Ramaiya K, Agoudavi K, Guwatudde D, Bahendeka SK, Mutungi G, Geldsetzer P, Levitt NS, Salomon JA, Yudkin JS, Vollmer S, Bärnighausen T.

Lancet Diabetes Endocrinol. 2016 Nov;4(11):903-912. doi: 10.1016/S2213-8587(16)30181-4. Epub 2016 Oct 7.

PMID:
27727123
23.

Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis.

Basu S, Shankar V, Yudkin JS.

Lancet Diabetes Endocrinol. 2016 Nov;4(11):922-932. doi: 10.1016/S2213-8587(16)30270-4. Epub 2016 Oct 4.

24.

Perivascular fat in human muscle.

Meijer RI, Serne EH, Yudkin JS, van Hinsbergh VW, Smulders YM, Eringa EC.

Lancet Diabetes Endocrinol. 2016 Nov;4(11):958. doi: 10.1016/S2213-8587(15)00520-3. Epub 2016 Feb 24. No abstract available.

PMID:
26928650
25.

Diabetes mellitus in Zambia and the Western Cape province of South Africa: Prevalence, risk factors, diagnosis and management.

Bailey SL, Ayles H, Beyers N, Godfrey-Faussett P, Muyoyeta M, du Toit E, Yudkin JS, Floyd S.

Diabetes Res Clin Pract. 2016 Aug;118:1-11. doi: 10.1016/j.diabres.2016.05.001. Epub 2016 May 7.

26.

"Prediabetes": Are There Problems With This Label? Yes, the Label Creates Further Problems!

Yudkin JS.

Diabetes Care. 2016 Aug;39(8):1468-71. doi: 10.2337/dc15-2113.

PMID:
27457638
27.

Liberating data: the WHO response - Authors' reply.

Davies J, Yudkin JS, Atun R.

Lancet Diabetes Endocrinol. 2016 Aug;4(8):648-649. doi: 10.1016/S2213-8587(16)30114-0. Epub 2016 Jun 16. No abstract available.

PMID:
27318674
28.

Guidelines for treating risk factors should include tools for shared decision making.

Yudkin JS, Kavanagh J, McCormack JP.

BMJ. 2016 Jun 14;353:i3147. doi: 10.1136/bmj.i3147. No abstract available.

PMID:
27302041
29.

Liberating data: the crucial weapon in the fight against NCDs.

Davies J, Yudkin JS, Atun R.

Lancet Diabetes Endocrinol. 2016 Mar;4(3):197-198. doi: 10.1016/S2213-8587(16)00037-1. Epub 2016 Jan 28. No abstract available.

PMID:
26827114
30.

Alternative Strategies to Achieve Cardiovascular Mortality Goals in China and India: A Microsimulation of Target- Versus Risk-Based Blood Pressure Treatment.

Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA.

Circulation. 2016 Mar 1;133(9):840-8. doi: 10.1161/CIRCULATIONAHA.115.019985. Epub 2016 Jan 13.

31.

Preventing cardiovascular events with empagliflozin: at what cost?

Naci H, Basu S, Yudkin JS.

Lancet Diabetes Endocrinol. 2015 Dec;3(12):931. doi: 10.1016/S2213-8587(15)00439-8. No abstract available.

PMID:
26590682
32.

Rethinking the appraisal and approval of drugs for type 2 diabetes.

Naci H, Lehman R, Wouters OJ, Goldacre B, Yudkin JS.

BMJ. 2015 Oct 9;351:h5260. doi: 10.1136/bmj.h5260. Review. No abstract available.

PMID:
26452524
33.

Ten Commandments for patient-centred treatment.

Lehman R, Tejani AM, McCormack J, Perry T, Yudkin JS.

Br J Gen Pract. 2015 Oct;65(639):532-3. doi: 10.3399/bjgp15X687001. No abstract available.

34.

Associations of birth weight, linear growth and relative weight gain throughout life with abdominal fat depots in adulthood: the 1982 Pelotas (Brazil) birth cohort study.

Araújo de França GV, De Lucia Rolfe E, Horta BL, Gigante DP, Yudkin JS, Ong KK, Victora CG.

Int J Obes (Lond). 2016 Jan;40(1):14-21. doi: 10.1038/ijo.2015.192. Epub 2015 Sep 23.

35.
36.

Diabetes prevention in England.

Yudkin JS, Millett C.

Lancet Diabetes Endocrinol. 2015 Jul;3(7):502. doi: 10.1016/S2213-8587(15)00211-9. No abstract available.

PMID:
26138168
37.

In defence of NICE draft type 2 diabetes guidelines.

Beran D, Yudkin JS.

Lancet Diabetes Endocrinol. 2015 Jun;3(6):406. doi: 10.1016/S2213-8587(15)00131-X. No abstract available.

PMID:
26003753
38.

Insulin-induced changes in skeletal muscle microvascular perfusion are dependent upon perivascular adipose tissue in women.

Meijer RI, Serné EH, Korkmaz HI, van der Peet DL, de Boer MP, Niessen HW, van Hinsbergh VW, Yudkin JS, Smulders YM, Eringa EC.

Diabetologia. 2015 Aug;58(8):1907-15. doi: 10.1007/s00125-015-3606-8. Epub 2015 May 24.

39.

The health system and population health implications of large-scale diabetes screening in India: a microsimulation model of alternative approaches.

Basu S, Millett C, Vijan S, Hayward RA, Kinra S, Ahuja R, Yudkin JS.

PLoS Med. 2015 May 19;12(5):e1001827; discussion e1001827. doi: 10.1371/journal.pmed.1001827. eCollection 2015 May.

40.

Politics, medical journals, the medical profession and the Israel lobby.

Yudkin JS, Leaning J.

BMJ. 2015 May 12;350:h2377. doi: 10.1136/bmj.h2377. No abstract available.

PMID:
25985332
41.

Comment on Cefalu et Al. The alarming and rising costs of diabetes and prediabetes: a call for action! Diabetes care 2014;37:3137-3138.

Yudkin JS, Montori VM.

Diabetes Care. 2015 May;38(5):e81. doi: 10.2337/dc14-2910. No abstract available.

PMID:
25908164
42.

The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy.

Schmidt TA, Yudkin JS.

Lancet Diabetes Endocrinol. 2015 Mar;3(3):168. doi: 10.1016/S2213-8587(15)00006-6. No abstract available.

PMID:
25702245
43.

Cardiovascular and all-cause mortality in relation to various anthropometric measures of obesity in Europeans.

Song X, Jousilahti P, Stehouwer CD, Söderberg S, Onat A, Laatikainen T, Yudkin JS, Dankner R, Morris R, Tuomilehto J, Qiao Q; DECODE Study Group.

Nutr Metab Cardiovasc Dis. 2015 Mar;25(3):295-304. doi: 10.1016/j.numecd.2014.09.004. Epub 2014 Sep 20.

PMID:
25315666
44.

Improving global access to medicines for non-communicable diseases.

Beran D, Perrin C, Billo N, Yudkin JS.

Lancet Glob Health. 2014 Oct;2(10):e561-2. doi: 10.1016/S2214-109X(14)70189-5. No abstract available.

45.

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes.

Yudkin JS, Vijan S, Sussman JB, Lehman R, Goldacre BM.

Lancet. 2014 Sep 20;384(9948):1095. doi: 10.1016/S0140-6736(14)61671-8. No abstract available.

PMID:
25241716
46.

Lack of impact of angiotensin-converting enzyme gene polymorphism and salt intake on insulin resistance and limb blood flow.

Foo M, Coppack SW, Denver AE, Bulmer K, Yudkin JS.

Clin Endocrinol (Oxf). 2015 Jan;82(1):76-83. doi: 10.1111/cen.12595. Epub 2014 Nov 3.

PMID:
25154650
47.

The epidemic of pre-diabetes: the medicine and the politics.

Yudkin JS, Montori VM.

BMJ. 2014 Jul 15;349:g4485. doi: 10.1136/bmj.g4485. No abstract available. Erratum in: BMJ. 2014;349:g4683.

48.

Rigorous science is needed to justify the centralisation of services.

Yudkin JS.

BMJ. 2014 Jul 1;349:g4324. doi: 10.1136/bmj.g4324. No abstract available.

PMID:
24986867
49.

Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.

Vijan S, Sussman JB, Yudkin JS, Hayward RA.

JAMA Intern Med. 2014 Aug;174(8):1227-34. doi: 10.1001/jamainternmed.2014.2894.

50.

Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.

Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND.

JAMA. 2014 Jun 11;311(22):2331-3. doi: 10.1001/jama.2014.6316. No abstract available.

Supplemental Content

Loading ...
Support Center